Corroboration of naringin effects on the intestinal absorption and pharmacokinetic behavior of candesartan cilexetil solid dispersions using in-situ rat models

References

• Michel B. Angiotensin II type 1 receptor blockers. Circulation 2001;103:904–12
   PubMed Web of Science ®Google Scholar
• Ripley TL, Chonlahan JS, Germany RE. Candesartan in heart failure. Clin Interv Aging 2006;1:357–66
   PubMed Web of Science ®Google Scholar
• Sharon S, Alexandra LS. Candesartan cilexetil: an angiotensin II-receptor blocker. Am J Health Syst Pharm 2000;157:739–46
   Google Scholar
• Contreras F, Cabrera J, Ospino N, et al. Role of angiotensin II AT1 receptor blockers in the treatment of arterial hypertension. Am J Ther 2003;10:401–8
   PubMedGoogle Scholar
• Bakris G. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. Clin Hypertens 2001;3:16–21
   PubMedGoogle Scholar
• McClellan KJ, Goa KL. Candesartan cilexetil: a review of its use in essential hypertension. Drugs 1998;56:847–69
   PubMed Web of Science ®Google Scholar
• Vijaykumar N, Raviraj P, Venkateshwarlu V, Harisudhan T. Development and characterization of solid oral dosage form incorporating candesartan cilexetil. Pharm Dev Technol 2009;14:290–8
   PubMed Web of Science ®Google Scholar
• Zhang Z, Gao F, Bu H, et al. Solid lipid nanoparticles loading candesartan cilexetil enhances oral bioavailability: in vitro characteristics and absorption mechanism in rats. Nanomedicine 2012;8:740–7
   PubMed Web of Science ®Google Scholar
• Lee BS, Kang MJ, Choi WS, et al. Solubilized formulation of olmesartan medoxomil for enhancing oral bioavailability. Arch Pharm Res 2009;32:1629–35
   PubMed Web of Science ®Google Scholar
• Kamiyama E, Nakai D, Mikkaichi T, et al. Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes. Life Sci 2010;86:52–8
   PubMed Web of Science ®Google Scholar
• Zhou L, Chen X, Gu Y, Liang J. Transport characteristics of candesartan in human intestinal Caco-2 cell line. Biopharm Drug Dispos 2009;30:259–64
   PubMed Web of Science ®Google Scholar
• Shaikh SM, Avachat AM. Enhancement of solubility and permeability of candesartan cilexetil by using different pharmaceutical interventions. Curr Drug Deliv 2011;8:346–53
   PubMed Web of Science ®Google Scholar
• Arias MJ, Gines JM, Moyano JR, Rabasco AM. The application of solid dispersion technique with D-mannitol to the improvement in oral absorption of triamterene. J Drug Target 1994;2:45–51
   PubMed Web of Science ®Google Scholar
• Zerrouk N, Chemtob C, Arnaud P, et al. In vitro and in vivo evaluation of carbamazepine-PEG 6000 solid dispersions. Int J Pharm 2001;225:49–62
   PubMed Web of Science ®Google Scholar
• Palmieri GF, Cantalamessa F, Di Martino P, et al. Lonidamine solid dispersions: in vitro and in vivo evaluation. Drug Dev Ind Pharm 2002;28:1241–50
   PubMed Web of Science ®Google Scholar
• Lee S, Nam K, Kim MS, et al. Preparation and characterization of solid dispersions of itraconazole by using aerosol solvent extraction system for improvement in drug solubility and bioavailability. Arch Pharm Res 2005;28:866–74
   PubMed Web of Science ®Google Scholar
• Streubel A, Siepmann J, Bodmeier R. Drug delivery to the upper small intestine window using gastroretentive technologies. Curr Opin Pharmacol 2006;6:501–8
   PubMed Web of Science ®Google Scholar
• Dahan A, Amidon, GL. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol 2009;297:G371–7
   PubMed Web of Science ®Google Scholar
• Hunter J, Hirst BH. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv Drug Deliv Rev 1997;25:129–57
   Web of Science ®Google Scholar
• Kunta JR, Sinko PJ. Intestinal drug transporters: in vivo function and clinical importance. Curr Drug Metab 2004;5:109–24
   PubMed Web of Science ®Google Scholar
• Chan LM, Lowes S, Hirst BH. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 2004;21:25–51
   PubMed Web of Science ®Google Scholar
• Van Asperen J, Van Tellingen O, Van der Valk MA, et al. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin Cancer Res 1998;4:2293–7
   PubMed Web of Science ®Google Scholar
• Malingre MM, Richel DJ, Beijnen JH, et al. Co-administration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol 2001;19:1160–6
   PubMed Web of Science ®Google Scholar
• Nakagami T, Yasui-Furukori N, Saito M, et al. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther 2005;78:43–51
   PubMed Web of Science ®Google Scholar
• Arima H, Yunomae K, Hirayama F, Uekama K. Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus. J Pharmacol Exp Ther 2001;297:547–55
   PubMed Web of Science ®Google Scholar
• Hugger ED, Audus KL, Borchardt RT. Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers. J Pharm Sci 2002;91:1980–90
   PubMed Web of Science ®Google Scholar
• Hugger ED, Novak BL, Burton PS, et al. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J Pharm Sci 2002;91:1991–2002
   PubMed Web of Science ®Google Scholar
• Hugger ED, Cole CJ, Raub TJ, et al. Automated analysis of polyethylene glycol-induced inhibition of P-glycoprotein activity in vitro. J Pharm Sci 2003;92:21–6
   PubMed Web of Science ®Google Scholar
• Johnson BM, Charman WN, Porter CJ. An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS PharmSci 2002;4:193–205
   Google Scholar
• Lo YL, Huang JD. Effects of sodium deoxycholate and sodium caprate on the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. Biochem Pharmacol 2000;59:665–72
   PubMed Web of Science ®Google Scholar
• Nerurkar MM, Burton PS, Borchardt RT. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm Res 1996;13:528–34
   PubMed Web of Science ®Google Scholar
• Nerurkar MM, Ho NF, Burton PS, et al. Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells. J Pharm Sci 1997;86:813–21
   PubMed Web of Science ®Google Scholar
• Rege BD, Kao JP, Polli JE. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci 2002;16:237–46
   PubMed Web of Science ®Google Scholar
• Wagner D, Spahn-Langguth H, Hanafy A, et al. Intestinal drug efflux: formulation and food effects. Adv Drug Del Rev 2001;50:S13–31
   PubMed Web of Science ®Google Scholar
• Spahn-Langguth H, Langguth P. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur J Pharm Sci 2001;12:361–7
   PubMed Web of Science ®Google Scholar
• Takanaga H, Ohnishi A, Matsuo H, Sawada Y. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells. Biol Pharm Bull 1998;21:1062–6
   PubMed Web of Science ®Google Scholar
• Gurunath S, Baswaraj KN, Patil PA. Enhanced solubility and intestinal absorption of candasartan cilexetil solid dispersions using everted rat intestinal sacs. Saudi Pharm J 2014 . [Epub ahead of print]. DOI: 10.1016/j.jsps.2013.03.006
   PubMed Web of Science ®Google Scholar
• Gurunath S, Baswaraj KN, Patil PA. Oral bioavailability and intestinal absorption of candesartan cilexetil: role of naringin as p-glycoprotein inhibitor. Drug Dev Ind Pharm 2014 . [Epub ahead of print]. DOI: 10.3109/03639045.2013.850716
   Web of Science ®Google Scholar
• Li M, Si L, Pan H, et al. Excipients enhance intestinal absorption of ganciclovir by P-gp inhibition: assessed in vitro by everted gut sac and in situ by improved intestinal perfusion. Int J Pharm 2011;403:37–45
   PubMed Web of Science ®Google Scholar
• Hanafy A, Langguth P, Spahn-Langguth H. Pretreatment with potent P-glycoprotein ligands may increase intestinal secretion in rats. Eur J Pharm Sci 2001;12:405–15
   PubMed Web of Science ®Google Scholar
• Asada H, Douen T, Waki M, et al. Absorption characteristics of chemically modified-insulin derivatives with various fatty acids in the small and large intestine. J Pharm Sci 1995;84:682–7
   PubMed Web of Science ®Google Scholar
• Fetih G, Habib F, Okada N, et al. Nitric oxide donors can enhance the intestinal transport and absorption of insulin and [Asu (1,7)]-eel calcitonin in rats. J Control Release 2005;106:287–97
   PubMed Web of Science ®Google Scholar
• Tozaki H, Odoriba T, Iseki T, et al. Use of protease inhibitors to improve calcitonin absorption from the small and large intestine in rats. J Pharm Pharmacol 1998;50:913–20
   PubMed Web of Science ®Google Scholar
• FDA. Guidance for industry: dissolution testing of immediate release solid oral dosage forms. US Department of Health and Human Services, Centre for Drug Evaluation and Research (CEDER); 1997
   Google Scholar
• ICH (Q2R1). Guideline on validation of analytical procedures: text and methodology. Proceedings of the International Conference on Harmonization, Geneva; 2007
   Google Scholar
• Zakeri-Milani P, Barzegar-Jalali M, Tajerzadeh H, et al. Simultaneous determination of naproxen, ketoprofen and phenol red in samples from rat intestinal permeability: HPLC method development and validation. J Pharm Biom Anal 2005;39:624–30
   PubMed Web of Science ®Google Scholar
• Benet LZ, Wu CY, Hebert MF, Wacher VJ. Intestinal drug metabolism and anti-transport processes: a potential paradigm shift in oral drug delivery. J Control Release 1996;39:139–43
   Web of Science ®Google Scholar
• Benet LZ, Cummins CL. The drug efflux-metabolism alliance: bio-chemical aspects. Adv Drug Deliv Rev 2001;50:S3–11
   PubMed Web of Science ®Google Scholar
• Zakeri-Milani P, Valizadeh H, Tajerzadeh H, et al. Predicting human intestinal permeability using single-pass intestinal perfusion in rat. J Pharm Pharm Sci 2007;10:368–79
   PubMed Web of Science ®Google Scholar
• Varma MVS, Kapoor N, Sarkar M, Panchagnula R. Simultaneous determination of digoxin and permeability markers in rat in situ intestinal perfusion samples by RP-HPLC. J Chromatogr B 2004;813:347–52
   PubMed Web of Science ®Google Scholar
• Salphati L, Childers K, Pan L, et al. Evaluation of a single-pass intestinal-perfusion method in rat for the prediction of absorption in man. J Pharm Pharmacol 2001;53:1007–13
   PubMed Web of Science ®Google Scholar
• Swenson ES, Milisen WB, Curatolo W. Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility. Pharm Res 1994;11:132–42
   Google Scholar
• Yamamoto A, Uchiyama T, Nishikawa R, et al. Effectiveness and toxicity screening of various absorption enhancers in the rat small intestine: effects of absorption enhancers on the intestinal absorption of phenol red and the release of protein and phospholipids from the intestinal membrane. J Pharm Pharmacol 1996;48:1285–9
   PubMed Web of Science ®Google Scholar
• Lehmann FG, Hufnagel H, Lorenz-Meyer H. Fecal intestinal alkaline phosphatase: a parameter for toxic damage of the small intestinal mucosa. Digestion 1981;21:156–62
   PubMed Web of Science ®Google Scholar
• Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000;14:S73–86
   PubMed Web of Science ®Google Scholar
• Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004;75:13–33
   PubMed Web of Science ®Google Scholar